1. Identification of Dihydroquinolizinone Derivatives with Cyclic Ether Moieties as New anti-HBV Agents. Qin, X., L. Yang, X. Ma, B. Jiang, S. Wu, A. Wang, S. Xu, W. Wu, H. Song, N. Du, K. Lv, Y. Li, and M. Liu. European Journal of Medicinal Chemistry, 2022. 238: 114518. PMID[35700597].
[PubMed]. HBV_06_2022.
2. Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action. Toyama, M., K. Watashi, M. Ikeda, A. Yamashita, M. Okamoto, K. Moriishi, M. Muramatsu, T. Wakita, A. Sharon, and M. Baba. Antimicrobial Agents of Chemotherapy, 2022. 66(6): e0207321. PMID[35604213]. PMCID[PMC9211404].
[PubMed]. HBV_06_2022.
3. Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity. Yuan, S.Y., H.B. Yu, Z. Yang, Y.P. Qin, J.H. Ren, S.T. Cheng, F. Ren, B.Y.K. Law, V.K.W. Wong, J.P.L. Ng, Y.J. Zhou, X. He, M. Tan, Z.Z. Zhang, and J. Chen. Frontiers in Pharmacology, 2022. 13: 837115. PMID[35721154]. PMCID[PMC9204083].
[PubMed]. HBV_06_2022.
4. IFN- α Inhibits HBV Transcription and Replication by Promoting HDAC3-mediated De-2-Hydroxyisobutyrylation of Histone H4K8 on HBV cccDNA Minichromosome in Liver. Zhao, L.N., H.F. Yuan, Y.F. Wang, H.L. Yun, W. Zheng, Y. Yuan, Y. Geng, M. Zhao, L.Y. Feng, and X.D. Zhang. Acta Pharmacologia Sinica, 2022. 43(6): p. 1484-1494. PMID[34497374]. PMCID[PMC9160025].
[PubMed]. HBV_06_2022.
Patent Citations
5. Fused Nitrogen Heterocyclic Derivatives and Their Use in the Treatment of HBV Infection. Liu, L., G. Deng, C. Lu, B. Tang, Z. Liu, Z. Cheng, S.C. Grosse, K. Vandyck, E. Jacoby, T.H.M. Jonckers, P.J.-M.B. Raboisson, S.D. Kuduk, and L.G. Deratt. Patent. 2022. 2021-CN134798 2022116997: 95pp.
[Patent]. HBV_06_2022.
6. Preparation of Fused Heterocyclic Compounds as HBV Inhibitors. Liu, L., G. Deng, C. Lu, B. Tang, Z. Liu, K. Vandyck, S.C. Grosse, T.H.M. Jonckers, E. Jacoby, S.D. Kuduk, P.J.-M.B. Raboisson, and L.G. Deratt. Patent. 2022. 2021-CN134801 2022116999: 78pp.
[Patent]. HBV_06_2022.
7. Preparation of Fused Heterocyclic Compounds as HBV Inhibitors. Liu, L., G. Deng, C. Lu, K. Vandyck, Z. Liu, T.H.M. Jonckers, S.C. Grosse, S.D. Kuduk, E. Jacoby, L.G. Deratt, and P.J.-M.B. Raboisson. Patent. 2022. 2021-CN134799 2022116998: 98pp.
[Patent]. HBV_06_2022.
8. Preparation of Tricyclic Compounds for Treatment of Hepatitis B and D. Vendeville, S., Y. Debing, and P.J.-M.B. Raboisson. Patent. 2022. 2021-US60366 2022115384: 373pp.
[Patent]. HBV_06_2022.